Drug intelligence / Profile preview

BPI-43487

Development stage: Unknown
Lead developer: Betta Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

BPI-43487 is an orally bioavailable, highly selective small molecule inhibitor of Fibroblast Growth Factor Receptor 4 (FGFR4), developed by Beta Pharma. It is designed to target the FGF19/FGFR4 signaling pathway, which is frequently dysregulated in certain cancers, particularly hepatocellular carcinoma (HCC). By binding to FGFR4, BPI-43487 inhibits the downstream signaling cascades that promote tumor cell proliferation and survival. It is currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors, with a focus on those harboring FGF19 amplification or FGFR4 overexpression, including hepatocellular carcinoma and cholangiocarcinoma.

Targets

FGFR4 (Fibroblast growth factor receptor 4)

Beyond the preview

Go deeper on BPI-43487.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPI-43487.

Explore the full profile